Table 1.

LSD1 inhibitors in clinical/preclinical trials.

S. No	LSD1 Inhibitor	Mode of Action	Single/Dual Inhibitor	Indications	Phase	Trial Number/Ref	Status
1	Bomedemstat (IMG-7289)	Irreversible	Single Inhibitor	AML SCLC AML	Phase I Phase I Phase I	NCT05597306 NCT05191797 NCT02842827	Recruiting Recruiting Completed
2.	SP2509/SP2577	Reversible	Single Inhibitor	ES Advanced Solid Tumors Gynecologic Cancers ES, CCS, LGFMS, SEF, EMC, AFH	Phase I Phase I Phase I Phase I/II	NCT03600649 NCT03895684 NCT04611139 NCT05266196	Recruiting Completed Withdrawn Enrolling
3.	GSK2879552	Irreversible	Single Inhibitor	SCLC MDS Leukemia	Phase I Phase I Phase I	NCT02034123 NCT02929498 NCT02177812	Terminated Terminated Terminated
4.	Tranylcypromine	Irreversible	Single inhibitor	AML AML AML	Phase I Phase I Phase I	NCT02273102 NCT02261779 NCT02717884	Completed Unknown Unknown
5.	ORY-1001	Irreversible	Single Inhibitor	AML AML SCLC AML	Phase I Phase II Phase II Phase I	NCT05546580 2018–000482-36 2018–000469-35 2013–002447-29	Recruiting Completed Completed Completed
6	Corin	Irreversible	Dual Inhibitor LSD1/HDACs	NSCLC	Phase II	NCT02264210	Recruiting
7	INCB059872	Irreversible	Single Inhibitor	Solid Tumors Solid Tumors, Hematologic Malignancy Relapsed ES	Phase II Phase I Phase I	NCT02959437 NCT02712905 NCT03514407	Terminated Terminated Terminated
8	GSK-LSD1	Irreversible	Single Inhibitor	BC HCC	Pre-Clinical Pre-Clinical	86 20	-
9	JBI-097	Irreversible	Dual Inhibitor LSD1/HDAC6	MM, Leukaemia	Pre-Clinical	62	-
10	ZY0511	Reversible	Single Inhibitor	HCC, CC	Pre-Clinical	94, 99	-
11	GSK690	Reversible	Single Inhibitor	NA	NA	69	-
12	NCD38	Irreversible	Single Inhibitor	GBM, EC	Pre-Clinical	45,88	-
13	Compound 5	Reversible	NA	NA	NA	64	-
14	Pargyline	Irreversible	Single inhibitor	KC	Pre-Clinical	97	-
15	MC_2580 DDP_38003	Irreversible	Single inhibitor	AML	Pre-Clinical	76	-
16	Clorgyline	Irreversible	Single inhibitor	PC	Pre-Clinical	98	-